Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDKM-100 in Advanced Hepatocellular Carcinoma
NCT05628545Phase 2Withdrawn
- Sponsor
- Guangdong Kongming Biotech
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic gamma delta T cells GDKM-100 in hepatocellular carcinoma (HCC), sponsored by Guangdong Kongming Biotech. Planned start Nov 2021; status: withdrawn.
02
Drugs
allogeneic gamma delta T cells GDKM-100
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05628545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628545.